Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Siow-ming Lee
JNCI Journal of the National Cancer Institute, 2013
View PDFchevron_right
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials
Francesco Massari, Diana Giannarelli
Critical Reviews in Oncology/Hematology, 2014
View PDFchevron_right
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
Elena Dragioti
DOAJ (DOAJ: Directory of Open Access Journals), 2021
View PDFchevron_right
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
Denis Soulières
Journal of Cellular and Molecular Medicine, 2014
View PDFchevron_right
Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
mingyang liu
Journal of thoracic disease, 2016
View PDFchevron_right
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Maria Barzelloni
Clinical lung cancer, 2017
View PDFchevron_right
EGFRPolymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis
Lyudmila Gulyaeva
Journal of Oncology, 2020
View PDFchevron_right
Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders
Chi-li Chung
PLoS ONE, 2013
View PDFchevron_right
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Luis Paz-ares
Journal of Cellular and Molecular Medicine, 2010
View PDFchevron_right
Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Lukas Amler
Cold Spring Harbor Symposia on Quantitative Biology, 2005
View PDFchevron_right
From Diagnostic‐Therapeutic Pathways to Real‐World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR‐Positive Non‐Small Cell Lung Cancer (MOST Study)
Alberto Bortolami
The Oncologist
View PDFchevron_right
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
Tetsuya Mitsudomi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis
Pedro Madureira
Oncotarget, 2018
View PDFchevron_right
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
Michele Tursi
Oncotarget, 2016
View PDFchevron_right
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer
Helena Linardou
Annals of Oncology, 2011
View PDFchevron_right
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
Tetsuya Mitsudomi
Journal of the National Cancer Institute, 2017
View PDFchevron_right
Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial
anuradha choughule
Indian Journal of Medical and Paediatric Oncology, 2018
View PDFchevron_right
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer
S. Rampal
Lung Cancer, 2013
View PDFchevron_right
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Jin-Hyuk Choi
The Korean journal of internal medicine, 2017
View PDFchevron_right
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer with G719X/L861Q/S768I Mutations
Ming-shyan Huang
Annals of Oncology, 2014
View PDFchevron_right
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis
Paola Sburlati
Anticancer research, 2009
View PDFchevron_right
Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
Hui Pan
Journal of thoracic disease, 2014
View PDFchevron_right
EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: How do we interpret the clinical and biomarker data?
Fiona Blackhall
Targeted Oncology, 2008
View PDFchevron_right
Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Javier Milara
The European Journal of Health Economics, 2019
View PDFchevron_right
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
Kathy Gately
Journal of Clinical Pathology, 2011
View PDFchevron_right
Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER
Ping Li
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2011
View PDFchevron_right
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
Francisco Pietro Oliveira Orlandi
Annals of Oncology, 2020
View PDFchevron_right
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
Yu-feng Wei
Journal of Cancer
View PDFchevron_right
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Branislav Perin
OncoTargets and Therapy, 2015
View PDFchevron_right
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Aung Naing
Oncotarget, 2013
View PDFchevron_right
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI)versusintercalated TKI with chemotherapy forEGFR-mutated nonsmall cell lung cancer
Frans Krouwels
ERJ Open Research
View PDFchevron_right
Survival Rate of Lung Adenocarcinoma Patients Receiving EGFR - Tyrosine Kinase Inhibitor Targeted Therapy
Chaerani Bahar
Jurnal Kedokteran Brawijaya
View PDFchevron_right